|
RBM15 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62447832963153E-12 |
| Normal-vs-Stage2 |
1.22124532708767E-15 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
5.608600E-01 |
| Stage1-vs-Stage3 |
4.871700E-02 |
| Stage1-vs-Stage4 |
1.190160E-01 |
| Stage2-vs-Stage3 |
4.168000E-01 |
| Stage2-vs-Stage4 |
4.446800E-01 |
| Stage3-vs-Stage4 |
9.427800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
9.72422142808682E-12 |
| Normal-vs-Asian |
<1E-12 |
| Caucasian-vs-AfricanAmerican |
6.284400E-01 |
| Caucasian-vs-Asian |
6.936000E-01 |
| AfricanAmerican-vs-Asian |
4.609200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
3.817600E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.22044604925031E-16 |
| Normal-vs-Age(41-60Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
2.40629999999076E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.245600E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.106830E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.113800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.265600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.082000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.187400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.61672999999807E-05 |
| Classical-VS-Follicular |
1.071650E-02 |
| Classical-VS-Other |
6.636200E-02 |
| Classical-VS-Normal |
1.62614366416847E-12 |
| Tall-VS-Follicular |
6.172300E-02 |
| Tall-VS-Other |
8.702800E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
3.748600E-01 |
| Follicular-VS-Normal |
1.62447832963153E-12 |
| Other-VS-Normal |
7.18869999971616E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
6.321600E-01 |
|
|
